Fasting and L-364,718 prevent cholecystokinin-induced elevations of plasma insulin levels.
Sulfated CCK-8 but not non-sulfated CCK-8 induced a dose-dependent increase in plasma insulin levels in fed mice. In fasted mice, however, the CCK peptides caused a non-significant to minimal elevation of plasma insulin. Refeeding fasted mice for 1 h prior to CCK-8-S administration was sufficient to cause a significant elevation of plasma insulin levels. The peripheral CCK antagonist, L-364,718, prevented the CCK-8-S-induced elevation of plasma insulin observed in fed mice. In conclusion, CCK produces a nutrition-dependent increase in plasma insulin levels in vivo via an action upon peripheral CCK receptors.
Reagan
J E
JE
Department of Microbial Pharmacometrics, Merck Sharp and Dohme Research Laboratories, West Point, PA 19486.
Robinson
J L
JL
Lotti
V J
VJ
Goldman
M E
ME
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D020109:Devazepide; D005215:Fasting; D007328:Insulin / Q000097:blood*; D008297:Male; D051379:Mice; D012844:Sincalide / Q000494:pharmacology*
D001570:Benzodiazepinones; D007328:Insulin; D002766:Cholecystokinin; D020109:Devazepide; D012844:Sincalide